Exhibit 10.2

Execution Version

SEVENTH AGREEMENT TO AMEND THE FLOATING RATE NOTE SUPPORT AGREEMENT

THIS SEVENTH AMENDMENT is made as of this 22nd day of April, 2011.

WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities
listed in Schedule A (together with Angiotech, the “Companies” and each a
“Company”), and (c) each of the other Consenting Noteholders party hereto, each
Consenting Noteholder being a holder of and/or investment advisor or manager
with investment discretion over Floating Rate Notes, executed a Floating Rate
Note Support Agreement dated as of October 29, 2010 concerning the principal
aspects of an Exchange of Floating Rate Notes (as amended by an Agreement to
Amend the Floating Rate Note Support Agreement dated November 29, 2010, a Second
Agreement to Amend the Floating Rate Note Support Agreement dated December 15,
2010, a Third Agreement to Amend the Floating Rate Note Support Agreement dated
January 11, 2011, a Fourth Agreement to Amend the Floating Rate Note Support
Agreement dated January 27, 2011, a Fifth Agreement to Amend the Floating Rate
Note Support Agreement dated February 7, 2011 and a Sixth Agreement to Amend the
Floating Rate Note Support Agreement dated February 22, 2011, the “Support
Agreement”);

AND WHEREAS, the Consenting Noteholders party to this seventh amendment (the
“Seventh Amendment”) wish to further amend the Support Agreement in the manner
set out in this Seventh Amendment;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Companies and the Consenting Noteholders
party hereto hereby agree as follows:

 

1. Capitalized Terms

Capitalized terms that are used but not otherwise defined herein shall have the
meanings ascribed thereto in the Support Agreement.

 

2. Consenting Noteholders Party to this Seventh Amendment

Each Consenting Noteholder party to this Seventh Amendment hereby represents and
warrants, severally and not jointly, to each of the other parties to this
Seventh Amendment (and acknowledges that each of the other parties to this
Seventh Amendment is relying upon such representations and warranties) that as
of the date hereof: (a) it either (i) is the sole legal and beneficial owner of
the principal amount of Floating Rate Notes disclosed to Goodmans LLP as of such
date, or (ii) has the investment and voting discretion with respect to the
principal amount of Floating Rate Notes disclosed to Goodmans LLP as of such
date; (b) it has the power and authority to bind the beneficial owner(s) of such
Floating Rate Notes to the terms of this Seventh Amendment; and (c) it has
authorized and instructed Goodmans LLP to advise Angiotech, in writing, of the
aggregate amount of Floating Rate Notes held by the Consenting Noteholders that
are party to this Seventh Amendment.

--------------------------------------------------------------------------------

3. Amendments to the Support Agreement

The Support Agreement is hereby amended as follows:

 

  (a) the definition of “Outside Date” on Schedule B to the Support Agreement is
hereby deleted and replaced with the following:

“Outside Date” means May 12, 2011.

 

4. Support Agreement to apply in full force and effect

Except as expressly modified by the terms of this Seventh Amendment, the terms
and conditions of the Support Agreement shall continue to apply in full force
and effect, unamended.

 

5. Miscellaneous

 

  (a) This Seventh Amendment shall be governed by and construed in accordance
with the laws of the Province of Ontario and the federal laws of Canada
applicable therein, without regard to principles of conflicts of law. Each of
the parties to this Seventh Amendment submits to the jurisdiction of the courts
of the Province of Ontario in any action or proceeding arising out of or
relating to this Seventh Amendment.

 

  (b) This Seventh Amendment may be signed in counterparts, each of which, when
taken together, shall be deemed an original. Execution of this Seventh Amendment
is effective if a signature is delivered by facsimile transmission or electronic
(e.g., pdf) transmission.

[The remainder of this page is intentionally left blank]

 

- 2 -

--------------------------------------------------------------------------------

This Seventh Amendment has been agreed and accepted on the date first written
above.

 

ANGIOTECH PHARMACEUTICALS, INC. By:  

  /s/ K. Thomas Bailey

 

  Name:     K. Thomas Bailey

  Title:       Chief Financial Officer

 

AFMEDICA, INC.;

AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.;

ANGIOTECH AMERICA, INC.;

ANGIOTECH BIOCOATINGS CORP.;

ANGIOTECH DELAWARE, INC.;

ANGIOTECH FLORIDA HOLDINGS, INC.;

ANGIOTECH PHARMACEUTICALS (US), INC.;

B.G. SULZLE, INC.;

MANAN MEDICAL PRODUCTS, INC.;

MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL, INC.;

QUILL MEDICAL, INC.;

SURGICAL SPECIALTIES CORPORATION;

SURGICAL SPECIALTIES PUERTO RICO, INC.; and

SURGICAL SPECIALTIES UK HOLDINGS LIMITED

By:  

  /s/ K. Thomas Bailey

 

  Name:     K. Thomas Bailey

  Title:       President

--------------------------------------------------------------------------------

ANGIOTECH INTERNATIONAL HOLDINGS CORP.; and

 

0741693 B.C. LTD.

By:  

  /s/ Jay Dent

 

  Name:     Jay Dent

  Title:       President